| Gene symbol | TNFSF9 | Synonyms | 4-1BB-L, CD137L, TNLG5A | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19p13.3 | dbXrefs | |
| Description | TNF superfamily member 9 | ||||
| GTO ID | GTC3999 |
| Trial ID | NCT04714983 |
| Disease | Colorectal Cancer | Breast Cancer | Melanoma |
| Altered gene | E1A|TNFSF9 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | DNX-2440 |
| Phase | Phase1 |
| Recruitment status | Suspended |
| Title | A Phase I Safety and Window-of-opportunity Study of Preoperative Intratumoral Injection of OX40-ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients With Resectable Liver Metastasis |
| Year | 2021 |
| Country | United States |
| Company sponsor | DNAtrix, Inc. |
| Other ID(s) | 2440LM-002 |
| Vector information | |||||||||||
|
|||||||||||
| Cohort 1 | |||||||
|
|||||||